CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

INTRODUCTION: Tamoxifen is one of the most effective adjuvant breast cancer therapies available. Its metabolism involves the phase I enzyme, cytochrome P4502D6 (CYP2D6), encoded by the highly polymorphic CYP2D6 gene. CYP2D6 variants resulting in poor metabolism of tamoxifen are hypothesised to reduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Abraham, Jean E, Maranian, Mel J, Driver, Kristy E, Platte, Radka, Kalmyrzaev, Bolot, Baynes, Caroline, Luccarini, Craig, Shah, Mitul, Ingle, Susan, Greenberg, David, Earl, Helena M, Dunning, Alison M, Pharoah, Paul DP, Caldas, Carlos
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949659/
https://www.ncbi.nlm.nih.gov/pubmed/20731819
http://dx.doi.org/10.1186/bcr2629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949659/
https://www.ncbi.nlm.nih.gov/pubmed/20731819
http://dx.doi.org/10.1186/bcr2629

Ejemplares similares